Post-earnings recap
Reported
Thu, Mar 5, 2026
EPS actual
$-0.29
EPS est.
$-0.31
EPS surprise
+5.84%
1-day move
+36.28%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Tango Therapeutics I's earnings report showed a smaller-than-expected loss per share, which contributed to a significant stock increase of 36.28%. The positive stock reaction suggests that investors are encouraged by the company's progress and management's optimistic tone, despite the lack of revenue data and forward guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | +5.84% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, highlighting ongoing efforts to develop their product pipeline. They remain focused on strategic initiatives but did not provide specific guidance for the future.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.